ITL Limited 2016/17 First Half Results & ITL BioMedical Growth Update

ITL BioMedical’s EBITDA grew 54% to $2.5m. The division is expected to see strong growth continue as sales of its innovative products increase within the large and fast growing existing and potential new markets.